<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100021</url>
  </required_header>
  <id_info>
    <org_study_id>TA-017</org_study_id>
    <nct_id>NCT01100021</nct_id>
  </id_info>
  <brief_title>Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin</brief_title>
  <official_title>A Phase 1, Single-centre, Double-blind, Randomized, Placebo-controlled, Two-cohort, Two-period Crossover Study of the Hemodynamic Interactions Between Avanafil and Two α-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-aged Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if avanafil causes any changes in blood pressure and&#xD;
      pulse rate when taken with doxazosin or tamsulosin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum decrease in blood pressure after dosing</measure>
    <time_frame>30, 20, 10 min predose; 15, 30, 45, 60, 75, 90, 105, 120 min, 2.5, 3, 3.5, 4, 5, 6, 7, 10, 12, 18, and 24 hrs postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum decrease in blood pressure and pulse rate after dosing</measure>
    <time_frame>30, 20, 10 min predose; 15, 30, 45, 60, 75, 90, 105, 120 min, 2.5, 3, 3.5, 4, 5, 6, 7, 10, 12, 18, and 24 hrs postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>tamsulosin + avanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxazosin + avanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin and avanafil</intervention_name>
    <description>tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days</description>
    <arm_group_label>tamsulosin + avanafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin and avanafil</intervention_name>
    <description>doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day</description>
    <arm_group_label>Doxazosin + avanafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written Informed Consent.&#xD;
&#xD;
          2. Adult male subjects 40 to 65 years of age, inclusive.&#xD;
&#xD;
          3. A body weight of at least 50 kg and a body mass index (BMI) between 18 and 32 kg/m2,&#xD;
             inclusive [BMI will be calculated as weight in kg/(height in m)2].&#xD;
&#xD;
          4. Subjects are able to communicate with the Investigator, and to understand and comply&#xD;
             with all requirements of study participation.&#xD;
&#xD;
          5. Medically healthy, with no clinically significant screening results (e.g., laboratory&#xD;
             profiles, medical histories, ECGs, physical exam, etc.), in the opinion of the&#xD;
             Investigator in consultation with the Sponsor.&#xD;
&#xD;
          6. Male subjects should be willing to use a condom and spermicide during sexual activity&#xD;
             for 90 days after last dosing of avanafil and be willing to not donate sperm for 90&#xD;
             days after dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history or presence of significant cardiovascular (including thromboembolic&#xD;
             disorders), neurological, hematological, psychiatric, hepatic, gastrointestinal,&#xD;
             pulmonary, endocrine, immunologic or renal disease or other condition known to&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of drugs or&#xD;
             place the subjects at increased risk as determined by the Investigator.&#xD;
&#xD;
          2. Any clinically significant laboratory abnormalities as judged by the Investigator.&#xD;
             Inclusion of a subject with out of normal range laboratory values must be approved by&#xD;
             VIVUS prior to subject enrollment.&#xD;
&#xD;
          3. A predisposition to priapism, such as subjects with sickle cell disease or blood&#xD;
             dyscrasias.&#xD;
&#xD;
          4. Known history of cardiovascular or cerebrovascular event, any history of angina.&#xD;
&#xD;
          5. Subjects with episode(s) of fainting or vasovagal hypotension.&#xD;
&#xD;
          6. History or ECG evidence of any high-risk arrhythmia or ECG judged by the Investigator&#xD;
             to be clinically significant.&#xD;
&#xD;
          7. Hypertrophic obstructive or other clinically significant cardiomyopathy, moderate or&#xD;
             severe cardiac valvular disease.&#xD;
&#xD;
          8. Subjects whose pulse is lower than 55 bpm at screening or 50 bpm prior to dosing.&#xD;
&#xD;
          9. Acute illness, especially any infection, within 2 weeks of dosing.&#xD;
&#xD;
         10. Systolic blood pressure &lt; 90 or &gt;150 mmHg; diastolic blood pressure &lt; 50 or &gt; 95 mmHg&#xD;
             at screening or at check-in on Day -1 (2 rechecks are allowed).&#xD;
&#xD;
         11. Subjects with benign prostatic hyperplasia or orthostatic hypotension (as evidenced by&#xD;
             reduction of 20 mmHg or more in systolic blood pressure, reduction of 10 mmHg or more&#xD;
             in diastolic blood pressure, or evidence of cerebral hypoperfusion upon standing from&#xD;
             a seated position).&#xD;
&#xD;
         12. History of retinitis pigmentosa or nonarteritic anterior ischemic optic neuropathy.&#xD;
&#xD;
         13. Any history of bipolar disorder or psychosis, history of psychiatric hospitalization,&#xD;
             greater than one lifetime episode of major depression.&#xD;
&#xD;
         14. Hemoglobin &lt; 12.0 g/dL.&#xD;
&#xD;
         15. Subjects with liver function tests &gt; 1.5 ULN&#xD;
&#xD;
         16. Positive urine drug test and/or positive urine alcohol test at screening or at&#xD;
             check-in on Day -1.&#xD;
&#xD;
         17. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibodies (HCV) at screening.&#xD;
&#xD;
         18. Any history or presence of alcoholism or drug or substance abuse within 18 months or&#xD;
             as defined by the Investigator.&#xD;
&#xD;
         19. Allergy to or previously significant adverse events with PDE5 inhibitors, doxazosin&#xD;
             and tamsulosin or their constituents.&#xD;
&#xD;
         20. Use of any prescription or over-the-counter (OTC) medication, including herbal&#xD;
             products, within the 14 days prior to Day 1. Up to 2 g per day of acetaminophen is&#xD;
             allowed at the discretion of the Investigator.&#xD;
&#xD;
         21. Use of any drug in Appendix 1 (drugs known to have clinical significance in inhibiting&#xD;
             or inducing liver enzymes involved in drug metabolism [CYP P450]) within 30 days prior&#xD;
             to Day 1.&#xD;
&#xD;
         22. Blood donation or significant blood loss within 56 days prior to Day 1.&#xD;
&#xD;
         23. Plasma donation within 14 days prior to Day 1.&#xD;
&#xD;
         24. Any use of tobacco or nicotine products within 6 months prior to Day 1. Serum cotinine&#xD;
             levels &lt;10 ng/mL are considered to be consistent with no active smoking.&#xD;
&#xD;
         25. Any subject who received an investigational drug within 30 days or six half-lives,&#xD;
             whichever is longer, prior to Day 1.&#xD;
&#xD;
         26. Evidence of any clinically significant medical, psychiatric, social or other condition&#xD;
             by history, physical examination or laboratory studies that, in the opinion of the&#xD;
             Investigator, would contraindicate the administration of study medications, affect&#xD;
             compliance, interfere with study evaluations, limit study participation, or confound&#xD;
             the interpretation of study results.&#xD;
&#xD;
         27. Involvement in the planning and conduct of the study (applies to both VIVUS or&#xD;
             designee staff, or staff at the investigational site).&#xD;
&#xD;
         28. Previously participated in a trial with avanafil.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Sharples, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services Inc.,</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wes Day, PhD/VP of Clinical</name_title>
    <organization>Vivus, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

